A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840
Recruiting
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Research Site, San Diego, California +240 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
NCT05941520
Recruiting
This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer. The usual approach for patients at increased risk for breast cancer is to undergo yearly breast magnetic resonance imaging or ultrasound in addition to yearly mammogram. Premenopausal women at very high lifetime risk for breast cancer (greater than 50%) can consider preventive removal (mastectomy) of both breasts. Premenopa... Read More
Gender:
FEMALE
Ages:
35 years and above
Trial Updated:
04/04/2025
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +3 locations
Conditions: Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Register for Updates
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
NCT06238466
Recruiting
A study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD1705 in participants with dyslipidemia.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/04/2025
Locations: Research Site, Glendale, California +5 locations
Conditions: Cardiovascular
Register for Updates
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
NCT06433947
Recruiting
Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Banner MD Anderson, Gilbert, Arizona +7 locations
Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
Usefulness and Feasibility of Ultrasound in Office Laryngology Procedures
NCT06579989
Recruiting
Investigators will assess the usefulness of using ultrasound in office procedures for laryngology interventions. Participants who qualify will be adults who are undergoing superior laryngeal nerve block, injection laryngoplasty, swallowing evaluation, voice evaluation and voice therapy.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/04/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: Cough, Vocal Cord Atrophy, Vocal Cord Paresis, Vocal Cord Paralysis, Dysphagia, Dysphonia
Register for Updates
Patient-reported Outcomes of Donor Site Healing Using Different Palatal Protection Techniques
NCT06892496
Recruiting
This study has been initiated to evaluate the question, "What is the best way to protect the palate after a gum graft is removed?" The overall objective is to determine if there is a difference in PROMs of donor site healing using different palatal post-operative protection techniques.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Mucosal Erosion, Gingival Recession
Register for Updates
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
NCT02855476
Recruiting
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
Gender:
ALL
Ages:
Between 11 years and 75 years
Trial Updated:
04/03/2025
Locations: Cenexel, Englewood, Colorado +38 locations
Conditions: Huntington's Disease
Register for Updates
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
NCT04197934
Recruiting
This phase I trial studies the side effects and best dose of WSD0922-FU for the treatment of glioblastoma, anaplastic astrocytoma, or non-small cell lung cancer that has spread to the central nervous system (central nervous system metastases). WSD0922-FU is a targeted treatment which blocks the EGFR protein - a strategy that has led to a lot of benefit in patients with many different cancers. WSD0922-FU may also be able to get into cancers in the brain and spinal cord and help patients with brai... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH-Wildtype, Metastatic Malignant Neoplasm in the Central Nervous System, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT04704323
Recruiting
Introduction of immuno-chemotherapy in the treatment options of CLL and SLL changed the treatment paradigm of these diseases. Presently, first-line therapies for CLL/SLL include targeted therapies (e.g. ibrutinib, acalabrutinib) or combined immuno-chemotherapy regimens (e.g., fludarabine, cyclophosphamide, and rituximab for patients aged \<65 years without del17p/TP53 mutations or bendamustine and rituximab for patients ≥65 years who have additional comorbidities). Despite the gradual introduct... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +3 locations
Conditions: Lymphocytic Leukemia, Chronic, SLL
Register for Updates
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
NCT04947319
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: University of Alabama at Birmingham School of Medicine, Birmingham, Alabama +44 locations
Conditions: Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Register for Updates
FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
NCT05135091
Recruiting
This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/03/2025
Locations: Mayo Clinic Arizona Epilepsy Center, Phoenix, Arizona +28 locations
Conditions: Mesial Temporal Lobe Epilepsy
Register for Updates
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
NCT05365035
Recruiting
To learn if the combination of cladribine, cytarabine, venetoclax, and azacitidine can help to control higher-risk myelodysplastic syndrome (MDS) with excess blasts and/or higher-risk chronic myelomonocytic leukemia (CMML).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Myelodysplastic Syndromes, Myeloproliferative Chronic Myelomonocytic Leukemia
Register for Updates